We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

CEPHEID

Develops, manufactures, and markets molecular systems and tests for institutions to perform sophisticated genetic tes... read more Featured Products: More products

Download Mobile App




Rapid Diagnostic Testing Evaluated for Chlamydia and Gonorrhea

By LabMedica International staff writers
Posted on 23 Nov 2016
Prolonged turnaround time of Neisseria gonorrhoeae (NG) and Chlamydia trachomatis (CT) test results may delay time to notification and treatment of test-positive patients and result in unnecessary antimicrobial use in test-negative patients.

Nonculture methods, including nucleic acid amplification tests (NAAT), are widely available for the detection of genital NG/CT and are the preferred diagnostic tests, but with traditional NAAT, many health care facilities have a turnaround time between 1 and 4 days for results of NG/CT. More...
This prolonged time to results impacts time to patient and partner notification as well as treatment for test-positive patients who do not receive empiric therapy.

Scientists at the Cleveland Clinic (Cleveland, OH, USA) and their colleagues evaluated the impact of NG/CT rapid diagnostic testing (RDT) in an urban emergency department (ED) on treatment appropriateness, time to notification, and cost. They tested 200 patients in December 2013–January 2014 by traditional methods and these were compared with 200 patients in December 2014–January 2015 by RDT. Samples utilized by the ED included male urine or urethral samples and female endocervical samples.

Traditional testing was performed using the Gen-Probe Aptima Combo 2 for NG/CT Assay (Hologic, Bedford, MA, USA). The RDTs were performed using the GeneXpert CT/NG assay (Cepheid, Sunnyvale, CA, USA). The RDT was validated compared with the traditional testing method with sensitivity and specificity. A total of 53 patient specimens were collected and tested including male and female first-catch urine samples, patient-collected vaginal swabs, and provider-collected endocervical swabs.

The scientists found that there was a significant increase in treatment appropriateness in the RDT group, 72.5% versus 60% and time to results notification was significantly faster with a median of 17.4 versus 51.5 hours. Availability of test result prior to discharge was associated with increased treatment appropriateness. They also reported that the RDT would save approximately USD 37,000 annually. Of the 200 patients tested in the RDT group, only 40 (20%) were present in the ED at the time their results became available.

The authors concluded that implementation of a RDT for NG/CT in the ED significantly improved initial treatment appropriateness by sparing unnecessary antimicrobial use, decreased time to patient notification, and resulted in cost savings. Having test results prior to patient discharge from the ED was independently associated with receiving appropriate treatment. Interventions to increase the proportion of tests resulted prior to discharge are warranted to improve utilization of the RDT. The findings of this evaluation support the use of the NG/CT RDT as a component of antimicrobial stewardship in the ED. The study was published on October 18, 2016, in the journal Diagnostic Microbiology and Infectious Disease.

Related Links:
Cleveland Clinic
Hologic
Cepheid

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.